背景介绍 HVEM is a bidirectional switch regulating T-cell activation in a costimulatory or coinhibitory fashion whose outcome depends on the binding partner. HVEM can act as both receptor and ligand, the binding of endogenous ligand LIGHT or agonist antibodies to HVEM delivers a costimulatory signal; whereas the binding of HVEM to BTLA (IgSF) or CD160 on Effector T cells delivers a coinhibitory signal. LIGHT/HVEM axis are co-stimulatory immune checkpoint molecules extensively studied for cancer immunotherapy; LIGHT, either in the soluble monomer form or homotrimer expressed on the cell surface, can activate NF-kB through binding to HVEM; we have shown that LIGHT expressing cells are more potent and efficacious than the soluble LIGHT for activating HVEM expressed on T cell surface. 产品介绍 Recombinant clonal stable Jurkat T cell line expressing firefly luciferase gene under the control of 4 copies of NF-κB response elements with constitutive expression of human HVEM (Herpes Virus Entry Mediator, Tumor Necrosis Factor Receptor Superfamily Member 14, TNFRSF14, CD270, GenBank Accession No. NM_003820). Following activation by human HVEM ligand LIGHT, NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase reporter gene. Materials Required but Not Supplied: Assay Medium: Thaw Medium 2 (BPS Cat. #60184) LIGHT, His-Tag (Human) (BPS Cat. #71266 LIGHT-CHO Recombinant Cell Line (BPS Cat. # 79262) 96-well tissue culture-treated white clear-bottom assay plate One-Step luciferase assay system (BPS bioscience # 60690) or other luciferase reagents for measuring firefly luciferase activity Luminometer